These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2082488)

  • 1. Prevention of acute complications after percutaneous transluminal coronary angioplasty.
    Bourassa MG; Schwartz L; Lespérance J; Eastwood C; Kazim F
    Thromb Res Suppl; 1990; 12():51-8. PubMed ID: 2082488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Schwartz L; Bourassa MG; Lespérance J; Aldridge HE; Kazim F; Salvatori VA; Henderson M; Bonan R; David PR
    N Engl J Med; 1988 Jun; 318(26):1714-9. PubMed ID: 2967433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty.
    Lembo NJ; Black AJ; Roubin GS; Wilentz JR; Mufson LH; Douglas JS; King SB
    Am J Cardiol; 1990 Feb; 65(7):422-6. PubMed ID: 2407084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial.
    Heintzen MP; Heidland UE; Klimek WJ; Leschke M; Kelm M; Schwartzkopff B; Vester EG; Michel CJ; Strauer BE
    Heart; 2000 May; 83(5):551-6. PubMed ID: 10768906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    Steinhubl SR; Berger PB; Mann JT; Fry ET; DeLago A; Wilmer C; Topol EJ;
    JAMA; 2002 Nov; 288(19):2411-20. PubMed ID: 12435254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet agents and their effect on complications during or soon after percutaneous transluminal coronary angioplasty.
    Masotti M; Turá A; Crexells C; Oriol A
    J Int Med Res; 1991; 19(5):414-8. PubMed ID: 1748235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
    JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
    Maresta A; Balducelli M; Latini R; Bernardi G; Moccetti T; Sosa C; Barlera S; Varani E; Ribeiro da Silva EE; Monici Preti A; Maggioni AP;
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):375-82. PubMed ID: 15736248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive intracoronary dipyridamole in the interventional treatment of small coronary arteries: a prospectively randomized trial.
    Heidland UE; Heintzen MP; Michel CJ; Strauer BE
    Am Heart J; 2000 Jun; 139(6):1039-45. PubMed ID: 10827385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty.
    Schwartz L; Lesperance J; Bourassa MG; Eastwood C; Kazim F; Arafah M; Ganassin L
    Am Heart J; 1990 Feb; 119(2 Pt 1):232-6. PubMed ID: 2405609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of diltiazem on complications and restenosis after coronary angioplasty.
    O'Keefe JH; Giorgi LV; Hartzler GO; Good TH; Ligon RW; Webb DL; McCallister BD
    Am J Cardiol; 1991 Feb; 67(5):373-6. PubMed ID: 1994661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin.
    Klimt CR; Knatterud GL; Stamler J; Meier P
    J Am Coll Cardiol; 1986 Feb; 7(2):251-69. PubMed ID: 2868029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of secondary coronary prevention with dipyridamole and aspirin.
    Prentice CR
    Thromb Res Suppl; 1990; 12():43-9. PubMed ID: 2082486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy.
    White HD; French JK; Hamer AW; Brown MA; Williams BF; Ormiston JA; Cross DB
    J Am Coll Cardiol; 1995 Jan; 25(1):218-23. PubMed ID: 7798505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis.
    Hoberg E; Dietz R; Frees U; Katus HA; Rauch B; Schömig A; Schuler G; Schwarz F; Tillmanns H; Niebauer J
    Br Heart J; 1994 Mar; 71(3):254-60. PubMed ID: 8142195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty.
    Barnathan ES; Schwartz JS; Taylor L; Laskey WK; Kleaveland JP; Kussmaul WG; Hirshfeld JW
    Circulation; 1987 Jul; 76(1):125-34. PubMed ID: 2954724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.
    Lefkovits J; Blankenship JC; Anderson KM; Stoner GL; Talley JD; Worley SJ; Weisman HF; Califf RM; Topol EJ
    J Am Coll Cardiol; 1996 Oct; 28(4):849-55. PubMed ID: 8837559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.